157 related articles for article (PubMed ID: 15824163)
21. An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele.
Bertram CG; Gaut RM; Barrett JH; Pinney E; Whitaker L; Turner F; Bataille V; Dos Santos Silva I; J Swerdlow A; Bishop DT; Newton Bishop JA
J Invest Dermatol; 2002 Oct; 119(4):961-5. PubMed ID: 12406345
[TBL] [Abstract][Full Text] [Related]
22. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
[TBL] [Abstract][Full Text] [Related]
23. Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites.
Cohen Y; Rosenbaum E; Begum S; Goldenberg D; Esche C; Lavie O; Sidransky D; Westra WH
Clin Cancer Res; 2004 May; 10(10):3444-7. PubMed ID: 15161700
[TBL] [Abstract][Full Text] [Related]
24. Absence of BRAF and NRAS mutations in uveal melanoma.
Cruz F; Rubin BP; Wilson D; Town A; Schroeder A; Haley A; Bainbridge T; Heinrich MC; Corless CL
Cancer Res; 2003 Sep; 63(18):5761-6. PubMed ID: 14522897
[TBL] [Abstract][Full Text] [Related]
25. EDNRB gene variants and melanoma risk in two southern European populations.
Spica T; Fargnoli MC; Hetet G; Bertrand G; Formicone F; Descamps V; Wolkenstein P; Dupin N; Lebbe C; Basset-Seguin N; Saiag P; Cambien F; Grandchamp B; Peris K; Soufir N
Clin Exp Dermatol; 2011 Oct; 36(7):782-7. PubMed ID: 21507037
[TBL] [Abstract][Full Text] [Related]
26. The relationship between the epidermal growth factor (EGF) 5'UTR variant A61G and melanoma/nevus susceptibility.
Randerson-Moor JA; Gaut R; Turner F; Whitaker L; Barrett JH; Silva Idos S; Swerdlow A; Bishop DT; Bishop JA
J Invest Dermatol; 2004 Oct; 123(4):755-9. PubMed ID: 15373781
[TBL] [Abstract][Full Text] [Related]
27. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9.
Kumar R; Angelini S; Hemminki K
Oncogene; 2003 Dec; 22(58):9217-24. PubMed ID: 14681681
[TBL] [Abstract][Full Text] [Related]
28. DNA repair gene polymorphisms and genetic predisposition to cutaneous melanoma.
Povey JE; Darakhshan F; Robertson K; Bisset Y; Mekky M; Rees J; Doherty V; Kavanagh G; Anderson N; Campbell H; MacKie RM; Melton DW
Carcinogenesis; 2007 May; 28(5):1087-93. PubMed ID: 17210993
[TBL] [Abstract][Full Text] [Related]
29. Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma.
Pho L; Grossman D; Leachman SA
Curr Opin Oncol; 2006 Mar; 18(2):173-9. PubMed ID: 16462187
[TBL] [Abstract][Full Text] [Related]
30. Mutations of the BRAF gene in benign and malignant melanocytic lesions.
Yazdi AS; Palmedo G; Flaig MJ; Puchta U; Reckwerth A; Rütten A; Mentzel T; Hügel H; Hantschke M; Schmid-Wendtner MH; Kutzner H; Sander CA
J Invest Dermatol; 2003 Nov; 121(5):1160-2. PubMed ID: 14708620
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic BRAF and the tumor suppressor IGFBP7 in the genesis of atypical spitzoid nevomelanocytic proliferations.
Emley A; Yang S; Wajapeyee N; Green MR; Mahalingam M
J Cutan Pathol; 2010 Mar; 37(3):344-9. PubMed ID: 19788444
[TBL] [Abstract][Full Text] [Related]
32. Absence of exon 15 BRAF germline mutations in familial melanoma.
Lang J; Boxer M; MacKie R
Hum Mutat; 2003 Mar; 21(3):327-30. PubMed ID: 12619120
[TBL] [Abstract][Full Text] [Related]
33. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
34. On oncogenic BRAF, melanomagenesis and organ transplant recipients--"the more we know, the less we understand".
Mahalingam M
Eur J Dermatol; 2010; 20(2):143. PubMed ID: 20007066
[No Abstract] [Full Text] [Related]
35. Genetic alterations in melanocytic tumors.
Takata M; Saida T
J Dermatol Sci; 2006 Jul; 43(1):1-10. PubMed ID: 16750612
[TBL] [Abstract][Full Text] [Related]
36. Germline melanoma susceptibility and prognostic genes: a review of the literature.
Ward KA; Lazovich D; Hordinsky MK
J Am Acad Dermatol; 2012 Nov; 67(5):1055-67. PubMed ID: 22583682
[TBL] [Abstract][Full Text] [Related]
37. Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy.
Casula M; Colombino M; Satta MP; Cossu A; Lissia A; Budroni M; Simeone E; Calemma R; Loddo C; Caracò C; Mozzillo N; Daponte A; Comella G; Canzanella S; Guida M; Castello G; Ascierto PA; Palmieri G;
Eur J Cancer; 2007 Jan; 43(1):137-43. PubMed ID: 17055252
[TBL] [Abstract][Full Text] [Related]
38. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.
Dong J; Phelps RG; Qiao R; Yao S; Benard O; Ronai Z; Aaronson SA
Cancer Res; 2003 Jul; 63(14):3883-5. PubMed ID: 12873977
[TBL] [Abstract][Full Text] [Related]
39. Activating BRAF mutations in eruptive melanocytic naevi.
Sekulic A; Colgan MB; Davis MD; DiCaudo DJ; Pittelkow MR
Br J Dermatol; 2010 Nov; 163(5):1095-8. PubMed ID: 20716222
[TBL] [Abstract][Full Text] [Related]
40. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
